Developing kinase inhibitors has become very attractive for the pharmaceutical industry. Numerous drugs are in phase 3 and beyond, and due to the complexity of the kinome, there are still many opportunities for developing novel inhibitors. In order to stay ahead of the competition in the field it is necessary to keep updated on the current state of the art on lead compounds, as well as on the newest developments in structure-based drug design and the current assay technologies. In addition, discussions on target validation, on how to bring sense into the chemical space and on how to analyze the flood of data available will be presented.
Explore
Membership
